Bikunin Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor Alpha Induction in Macrophages

ABSTRACT Bikunin, a Kunitz-type protease inhibitor, exhibits anti-inflammatory activity in protection against cancer and inflammation. To investigate the molecular mechanism of this inhibition, we analyzed the effect of bikunin on tumor necrosis factor alpha (TNF-α) production in human peripheral mononuclear cells stimulated by lipopolysaccharide (LPS), an inflammatory inducer. Here, we show the following results. (i) LPS induced TNF-α expression in time- and dose-dependent manners through phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase pathways. (ii) Bikunin inhibits LPS-induced up-regulation of TNF-α protein expression in a dose-dependent manner, reaching 60% inhibition at the highest doses of bikunin tested (5.0 μM). (iii) Inhibition by bikunin of TNF-α induction correlates with the suppressive capacity of ERK1/2, JNK, and p38 signaling pathways, implicating repressions of at least three different signals in the inhibition. (iv) Bikunin blocks the induction of TNF-α target molecules interleukin-1β (IL-1β) and IL-6 proteins. (v) Bikunin is functional in vivo, and this glycoprotein blocks systemic TNF-α release in mice challenged with LPS. (vi) Finally, bikunin can prevent LPS-induced lethality. In conclusion, bikunin significantly inhibits LPS-induced TNF-α production, suggesting a mechanism of anti-inflammation by bikunin through control of cytokine induction during inflammation. Bikunin might be a candidate for the treatment of inflammation, including septic shock.

[1]  T. Terao,et al.  Bikunin plus paclitaxel markedly reduces tumor burden and ascites in mouse model of ovarian cancer , 2004, International journal of cancer.

[2]  T. Terao,et al.  Therapeutic efficacy of once‐daily oral administration of a Kunitz‐type protease inhibitor, bikunin, in a mouse model and in human cancer , 2004, Cancer.

[3]  S. Opal,et al.  Correlation between mortality and the levels of inter-alpha inhibitors in the plasma of patients with severe sepsis. , 2003, The Journal of infectious diseases.

[4]  Y. Saga,et al.  Bikunin Target Genes in Ovarian Cancer Cells Identified by Microarray Analysis* , 2003, The Journal of Biological Chemistry.

[5]  M. Suzuki,et al.  The Protease Inhibitor Bikunin, a Novel Anti-Metastatic Agent , 2003, Biological chemistry.

[6]  A. Kaczmarczyk,et al.  Inter-alpha-inhibitor, hyaluronan and inflammation. , 2003, Acta biochimica Polonica.

[7]  A. Kaczmarczyk,et al.  Inter-- inhibitor , hyaluronan and inflammation , 2003 .

[8]  M. Takigawa,et al.  Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascade. , 2002, European journal of biochemistry.

[9]  M. Takigawa,et al.  Kunitz-type Protease Inhibitor Bikunin Disrupts Phorbol Ester-induced Oligomerization of CD44 Variant Isoforms Containing Epitope v9 and Subsequently Suppresses Expression of Urokinase-type Plasminogen Activator in Human Chondrosarcoma Cells* , 2002, The Journal of Biological Chemistry.

[10]  I. Chaudry,et al.  Administration of human inter-alpha-inhibitors maintains hemodynamic stability and improves survival during sepsis. , 2002, Critical care medicine.

[11]  Q. Ma,et al.  Chemoprotection by Phenolic Antioxidants , 2002, The Journal of Biological Chemistry.

[12]  S. Sawada,et al.  Intravenous Ulinastatin Therapy for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Pediatric Patients , 2002, International Archives of Allergy and Immunology.

[13]  Q. Ma,et al.  Chemoprotection by Phenolic Antioxidants INHIBITION OF TUMOR NECROSIS FACTOR INDUCTION IN MACROPHAGES* , 2002 .

[14]  T. Calandra,et al.  MIF regulates innate immune responses through modulation of Toll-like receptor 4 , 2001, Nature.

[15]  M. Suzuki,et al.  Structure and function analysis of urinary trypsin inhibitor (UTI): identification of binding domains and signaling property of UTI by analysis of truncated proteins. , 2001, Biochimica et biophysica acta.

[16]  S. Kudo,et al.  Suppression of superantigen‐induced lung injury and vasculitis by preadministration of human urinary trypsin inhibitor , 2001, European journal of clinical investigation.

[17]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[18]  Y. Hirashima,et al.  Suppression of Urokinase Expression and Invasiveness by Urinary Trypsin Inhibitor Is Mediated through Inhibition of Protein Kinase C- and MEK/ERK/c-Jun-dependent Signaling Pathways* , 2001, The Journal of Biological Chemistry.

[19]  M. Feldmann,et al.  Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.

[20]  G. Kollias,et al.  TNF-α Induction by LPS Is Regulated Posttranscriptionally via a Tpl2/ERK-Dependent Pathway , 2000, Cell.

[21]  J. Schneider-Mergener,et al.  Synthetic Endotoxin-Binding Peptides Block Endotoxin- Triggered TNF-α Production by Macrophages In Vitro and In Vivo and Prevent Endotoxin-Mediated Toxic Shock , 2000, The Journal of Immunology.

[22]  K. Shimanuki,et al.  Evaluation of perioperative administration of methylprednisolone sodium succinate and urinary trypsin inhibitor for prevention of surgical stress. , 1999, Fukushima journal of medical science.

[23]  Y. Futamura,et al.  Protection against preterm delivery in mice by urinary trypsin inhibitor. , 1999, Obstetrics and gynecology.

[24]  M. Favata,et al.  Inhibition of MAP kinase kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes. , 1998, Journal of immunology.

[25]  M. Luster.  Inflammation, tumor necrosis factor, and toxicology. , 1998, Environmental health perspectives.

[26]  D. Caput,et al.  Interleukin-4 and -13 Inhibit Tumor Necrosis Factor-α mRNA Translational Activation in Lipopolysaccharide-induced Mouse Macrophages* , 1997, The Journal of Biological Chemistry.

[27]  M. Aibiki,et al.  Ulinastatin, a human trypsin inhibitor, inhibits endotoxin-induced thromboxane B2 production in human monocytes. , 1997, Critical care medicine.

[28]  B. Aggarwal,et al.  Tumor necrosis factors: developments during the last decade. , 1996, European cytokine network.

[29]  H. Schellekens,et al.  Cytokines and the immune response , 1996, Biotherapy.

[30]  H. Kobayashi,et al.  Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent. , 1995, British Journal of Cancer.

[31]  D. Laskin,et al.  Macrophages and inflammatory mediators in tissue injury. , 1995, Annual review of pharmacology and toxicology.

[32]  Amyj . Williams,et al.  NF-kappa B and I kappa B alpha: an inducible regulatory system in endothelial activation , 1994, The Journal of experimental medicine.

[33]  D. Colquhoun,et al.  Three case reports , 1993, The Medical journal of Australia.

[34]  F. Liew,et al.  Tumor necrosis factors: The molecules and their emerging role in medicine , 1992 .

[35]  B. Beutler,et al.  Tumor Necrosis Factor: The molecules and Their Emerging Role in Medicine , 1992 .

[36]  P. Baeuerle,et al.  Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B , 1990, Molecular and cellular biology.

[37]  R. Newton,et al.  Human Monocyte Production of Interleukin‐1: Parameters of the Induction of Interleukin‐1 Secretion by Lipopolysaccharides , 1986, Journal of leukocyte biology.

[38]  W. Reutter,et al.  Galactosamine-induced sensitization to the lethal effects of endotoxin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D. Keppler,et al.  Selective uridine triphosphate deficiency induced by D-galactosamine in liver and reversed by pyrimidine nucleotide precursors. Effect on ribonucleic acid synthesis. , 1974, The Journal of biological chemistry.